The scientific value of our study would have been improved if we had additionally measured the platelet count, the serum concentration of the gamma-glutamyl-transferase, and the serum albumin concentration, to have additional biomarkers for the presence of NAFLD. This evidence concerns the gene ALB and metabolic dysfunction-associated steatotic liver disease.